Patents/Inventors

David R. Lancia, Jr.

Boston, MAUS16 patents

16 Patents

US124798072025
Methods Using HDAC11 Inhibitors
VALO HEALTH, Inc.
0 cites
US123049042025
Bicyclic [4,6,0] Hydroxamic Acids as HDAC Inhibitors
VALO HEALTH, Inc.
0 cites
US122757152025
Pyridin-2(1h)-one Quinolinone Derivatives as Mutant-isocitrate Dehydrogenase Inhibitors
FORMA Therapeutics, Inc.
0 cites
US122641372025
3-aryl-4-amido-bicyclic [4,5,0] Hydroxamic Acids as HDAC Inhibitors
VALO HEALTH, Inc.
0 cites
US121280352024
Activating Pyruvate Kinase R
Novo Nordisk Health Care AG
0 cites
US121227782024
Activating Pyruvate Kinase R
Novo Nordisk Health Care AG
0 cites
US120714402024
Pyrrolopyrrole Compositions as Pyruvate Kinase (PKR) Activators
Novo Nordisk Health Care AG
0 cites
US120534582024
Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound
Novo Nordisk Health Care AG
0 cites
US120180302024
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-specific Protease 7 Inhibitors
VALO HEALTH, Inc.
0 cites
US119806112024
Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound
Novo Nordisk Health Care AG
0 cites
US119198392024
Alpha-cinnamide Compounds and Compositions as HDAC8 Inhibitors
VALO HEALTH, Inc.
0 cites
US118913652024
3-alkyl-4-amido-bicyclic [4,5,0] Hydroxamic Acids as HDAC Inhibitors
VALO HEALTH, Inc.
0 cites
US118447872023
Activating Pyruvate Kinase R
NOVO NORDISK HEALTH CARE AG
0 cites
US117390712023
Quinazolinones and Azaquinazolinones as Ubiquitin-specific Protease 7 Inhibitors
Valo Health, Inc.
0 cites
US117024122023
Bicyclic [4,6,0] Hydroxamic Acids as HDAC Inhibitors
Valo Health, Inc.
0 cites
US116492422023
Pyrrolopyrrole Compositions as Pyruvate Kinase (PKR) Activators
FORMA THERAPEUTICS, Inc.
0 cites